LGND insider trading
Purchases, sales and option exercises by company officers, directors and 10% owners, as reported to the SEC on Form 4.
- Insider purchases
- $0
- 0 open-market buys, last 30 days
- Insider sales
- $240.32K
- 2 open-market sales, last 30 days
- Buy / sell ratio
- 0.00
- Dollar value bought per dollar sold
- Cluster buys
- 0
- Symbols bought by 2+ insiders
3 transactions · Oct 12 – Nov 10
| Date | Symbol | Insider | Type | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|
| Nov 2 | LGND Ligand Pharmaceuticals Incorporated | Aryeh Jason Director | Sale | 700 | 320.43 | $224.30K | 108.76K | Form 4filing for Aryeh Jason (opens SEC.gov) |
| Nov 2 | LGND Ligand Pharmaceuticals Incorporated | Reardon Andrew CLO & Secretary | Exercise | 5,000 | — | — | 24.10K | Form 4filing for Reardon Andrew (opens SEC.gov) |
| Oct 30 | LGND Ligand Pharmaceuticals Incorporated | Aryeh Jason Director | Sale | 50 | 320.49 | $16.02K | 109.46K | Form 4filing for Aryeh Jason (opens SEC.gov) |
Source: SEC Form 4 filings. Value is shares × reported price; option exercises are often reported without a price. Awards, gifts and tax-withholding transactions are not shown. Not investment advice. Each row links to the original public filing on SEC.gov. Spotted an error, or want a record reviewed? Contact us.